No quarterly revenue total was found in Abpro Holdings, Inc.'s SEC filings.
Abpro Holdings, Inc. (ABPO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
$-940,000
+68.5% vs year-ago quarter
Operating cash flow
$-1.05M
-0.5% vs year-ago quarter
Free cash flow
—
EPS
$-0.16
+89.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
5.90M
-92.6% vs year-ago quarter
Net cash
$-389,000
Q4 FY2025
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ABPO (OTC), ABPWW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1893219
- Former names
- Atlantic Coastal Acquisition Corp. II (until Nov 12, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.2M | -$933,000 | -$1.9M | -$1.3M | -$2.3M |
| Net income | -$940,000 | -$1.0M | $5.6M | -$1.7M | -$3.0M |
| Diluted EPS | -$0.16 | -$0.23 | $2.08 | -$0.63 | -$1.56 |
| Operating cash flow | -$1.1M | -$2.1M | -$620,000 | -$2.8M | -$1.0M |
| Total assets | $5.2M | $6.9M | $1.1M | $1.7M | $3.5M |
| Stockholders' equity | -$3.5M | -$2.8M | -$8.8M | -$16.1M | -$17.5M |
| Cash and investments | $4.2M | $5.4M | $67,000 | $328,000 | $2.0M |
| Total debt | — | — | $456,000 | — | $149,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 1, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 25, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Listing notice
|
Jun 4, 2026 | May 28, 2026 |
| 10-Q | Quarterly report | May 20, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | May 1, 2026 | Dec 31, 2025 |
All 253 Abpro Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.